| Abstract | 8-alpha-amino-ergoline (CU 32-085) is a dopamine receptor agonist that should have fewer side effects than most other dopamine agonists. We studied the effect of this drug in 19 parkinsonian patients. In untreated or levodopa-treated patients, there was considerable improvement of akinesia, rigidity, and tremor; on-off symptoms also improved in the levodopa-treated patients. In patients pretreated with levodopa/bromocriptine, about half the dose of CU 32-085 was necessary to obtain the same therapeutic results, but there was no further improvement of on-off symptoms. Side effects were less pronounced than with bromocriptine; no circulatory disturbances and no psychotic episodes were observed. |
| Authors | E Schneider, K Hubener, P A Fischer |
| Journal | Neurology
(Neurology)
Vol. 33
Issue 4
Pg. 468-72
(Apr 1983)
ISSN: 0028-3878 UNITED STATES |
| PMID | 6682193
(Publication Type: Journal Article)
|
| Chemical References |
- Antiparkinson Agents
- Ergolines
- Levodopa
- Receptors, Dopamine
- Bromocriptine
- CQ 32085
|
| Topics |
- Activities of Daily Living
- Adult
- Aged
- Antiparkinson Agents
(administration & dosage, adverse effects, therapeutic use)
- Bromocriptine
(adverse effects, therapeutic use)
- Drug Therapy, Combination
- Ergolines
(adverse effects, therapeutic use)
- Female
- Humans
- Hypotension, Orthostatic
(chemically induced)
- Levodopa
(adverse effects, therapeutic use)
- Male
- Middle Aged
- Nausea
(chemically induced)
- Parkinson Disease
(drug therapy)
- Psychomotor Performance
(drug effects)
- Receptors, Dopamine
(drug effects)
|
